Serotonin regulates prostate growth through androgen receptor modulation.

Area of Science:

• Urology
• Endocrinology
• Cell Biology

Background:

• Benign prostatic hyperplasia (BPH) is a common condition in aging males, but its exact cause remains unclear.
• Serotonin (5-HT) is found in the prostate but its role in prostate physiology and BPH is unknown.
• Neuroendocrine cells and 5-HT levels are reduced in BPH compared to normal prostate tissue.

Purpose of the Study:

• To investigate the role of serotonin (5-HT) in prostate growth regulation.
• To explore the potential link between 5-HT depletion and the etiology of benign prostatic hyperplasia (BPH).

Main Methods:

• In vitro studies using rat prostate cells and human prostate cell lines treated with testosterone.
• In vivo studies using Tph1 knockout mice and wild-type mice.
• Analysis of androgen receptor (AR) expression and prostate mass.

Main Results:

• Serotonin (5-HT) was found to inhibit prostate growth by down-regulating androgen receptor (AR) expression in both rat and human prostate models.
• Tph1 knockout mice exhibited increased prostate mass and AR levels compared to wild-type mice.
• 5-HT treatment normalized prostate weight and AR levels in Tph1 knockout mice.

Conclusions:

• Serotonin (5-HT) acts as a negative regulator of prostate growth, primarily through the modulation of the androgen receptor (AR).
• Depletion of 5-HT may contribute to the development of benign prostatic hyperplasia (BPH).
• The serotonergic pathway in the prostate presents a potential novel therapeutic target for BPH.